TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCON
Previous Symbol
CUSIPN/A
Phone858-550-0780
Debt
Debt-to-Equity Ratio0.21
Current Ratio3.57
Quick Ratio3.57
Price-To-Earnings
Trailing P/E Ratio-0.96
Forward P/E Ratio-0.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.76 million
Price / Sales3.75
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.96 per share
Price / Book1.15
Profitability
EPS (Most Recent Fiscal Year)($1.14)
Net Income$-19,100,000.00
Net MarginsN/A
Return on Equity-108.08%
Return on Assets-66.40%
Miscellaneous
Employees25
Outstanding Shares29,870,000
Market Cap$33.76 million
OptionableNot Optionable
TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions
What is TRACON Pharmaceuticals' stock symbol?
TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."
How were TRACON Pharmaceuticals' earnings last quarter?
TRACON Pharmaceuticals Inc (NASDAQ:TCON) released its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.03. View TRACON Pharmaceuticals' Earnings History.
When is TRACON Pharmaceuticals' next earnings date?
What price target have analysts set for TCON?
1 brokerages have issued 1-year price targets for TRACON Pharmaceuticals' stock. Their predictions range from $8.00 to $8.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $8.00 in the next year. This suggests a possible upside of 627.3% from the stock's current price. View Analyst Price Targets for TRACON Pharmaceuticals.
What is the consensus analysts' recommendation for TRACON Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TRACON Pharmaceuticals.
Has TRACON Pharmaceuticals been receiving favorable news coverage?
News headlines about TCON stock have been trending neutral on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TRACON Pharmaceuticals earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.
Who are some of TRACON Pharmaceuticals' key competitors?
Some companies that are related to TRACON Pharmaceuticals include Erytech Pharma (ERYP), Jounce Therapeutics (JNCE), Organovo (ONVO), Fennec Pharmaceuticals (FENC), Nantkwest (NK), Champions Oncology (CSBR), Applied Genetic Technologies (AGTC), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Aptose Biosciences (APTO), Aevi Genomic Medicine (GNMX), BioCardia (BCDA), Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX) and Arsanis (ASNS).
Who are TRACON Pharmaceuticals' key executives?
TRACON Pharmaceuticals' management team includes the folowing people:
- Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 54)
- Dr. Sharon Real, Sr. VP of Product Devel. (Age 54)
- Ms. Bonne Adams, Sr. VP of Clinical Operations (Age 41)
- Mr. H. Casey Logan, Chief Bus. Officer (Age 46)
- Mr. Mark C. Wiggins, Chief Bus. Officer (Age 62)
When did TRACON Pharmaceuticals IPO?
(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
Who are TRACON Pharmaceuticals' major shareholders?
TRACON Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.71%) and Bridgeway Capital Management Inc. (0.33%). Company insiders that own TRACON Pharmaceuticals stock include Cross-Border Opportu Puissance, Enterprise Associates 14 New and William R Larue. View Institutional Ownership Trends for TRACON Pharmaceuticals.
Which major investors are buying TRACON Pharmaceuticals stock?
TCON stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Bridgeway Capital Management Inc.. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Cross-Border Opportu Puissance and Enterprise Associates 14 New. View Insider Buying and Selling for TRACON Pharmaceuticals.
How do I buy shares of TRACON Pharmaceuticals?
Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TRACON Pharmaceuticals' stock price today?
One share of TCON stock can currently be purchased for approximately $1.10.
How big of a company is TRACON Pharmaceuticals?
TRACON Pharmaceuticals has a market capitalization of $33.76 million and generates $8.76 million in revenue each year. The biopharmaceutical company earns $-19,100,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. TRACON Pharmaceuticals employs 25 workers across the globe.
What is TRACON Pharmaceuticals' official website?
How can I contact TRACON Pharmaceuticals?
TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]
MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)
MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.
